Friday, 22 Jun 2018

You are here

DEA Cracks Down on Illicit Fentanyl

Reuters reports that  U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.

We previously reported on increasing opioid overdose deaths (quadrupled from 1999 to 2015) and that most of these were from heroin and illicitly manufactured fentanyl. (https://buff.ly/2eHAjpn)

According to the U.S. Centers for Disease Control and Prevention, opioids were responsible for more than 33,000 U.S. deaths in 2015. Fentanyl is 50 times more potent than heroin and 100 times more potent than morphine.

Currently fentanyl is currently classified as a Schedule II drug, meaning it is highly addictive but has a medical purpose.

The DEA has now named illicit fentanyl as a Schedule 1 drug, along with heroin, means that is addictive and has no medicinal purpose.

These drugs are chemically similar to fentanyl and have similar effects on the human body, but chemists tweak their molecular structure so that they fall outside of the DEA’s scheduling regime, thereby skirting the law.

The new  emergency scheduling change of fentanyl analogues is only temporary and will last 2 years, but the DEA can either extend it for an additional year or make permanent schedule changes to protect the public.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Weight Loss Lessens Knee Pain in Obese

Obese knee osteoarthritis (OA) patients who lose > 20% of their weight were in significantly less pain, had better function and improved quality of life. 

Blacks Suffer When Pain is Poorly Defined

Racial discrimination was a key feature at a 2-day summit on pain management and the opioid crisis, hosted by the National Institutes of Health on Thursday and Friday.

Asheley Cockrell Skinner, PhD, of the Duke Clinical Research Institute in Durham, North Carolina, provided a broad overview of racial bias in opioid prescribing.

Prescription Drug Monitoring Programs Fail to Deter Opiate Abuse

A systematic review of prescription drug monitoring programs (PDMPs), advocated in the president's Prescription Drug Abuse Prevention Plan, fails to show evidence of efficacy in preventing nonfatal and fatal overdoses.

Measures of Opioid Misuse Predict Future Opioid Overdose and Death

The current issue of Annals of Internal Medicine examines patterns of potential opioid misuse that are associated with subsequent adverse outcomes nationally.

Researchers analyzed a 5% sample of Medicare beneficiaries who had an opioid prescription, without a cancer diagnosis.  Specifically the sought to correlate a diagnosis of opioid overdose with other measures of opioid misuse including:

Opioid Marketing & Meals Tied to Opioid Prescribing

A current study in JAMA Internal Medicine showed that while US physicians who received no opioid-related marketing payments had fewer opioid prescriptions in 2015 compared with 2014, those receiving such payments wrote for more opioid in 2015.